FLT3 and acute myeloid leukemia: Median age of 2L patients was 62 years (range 21–87 years); 190 (58%) were male, 115 (35%) were receiving secondary or therapy-related AML, and 38 (12%) had FLT3-ITD mutation at the R/R time (Table 1).